Ann E. Quinton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ann E. Quinton has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Michael John Peek
The Australian National University, College of Health and Medicine, Canberra
2 shared publications Adrienne Kirby
NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
1 shared publicationColleen-M Cook
Discipline of Obstetrics, Gynaecology and Neonatology, Sydney Medical School, The University of Sydney, Nepean Hospital, Penrith, NSW, Australia
1 shared publicationColleen-M. Cook
1 shared publicationC‐M Cook
Discipline of Obstetrics and Gynaecology, The University of Sydney, Nepean Hospital, Penrith, New South Wales, Australia
1 shared publicationMj Peek
Discipline of Obstetrics and Gynaecology, The University of Sydney, Nepean Hospital, Penrith, New South Wales, Australia
1 shared publication
Latest Publications
- 21 December 2010
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 31 (4) , 377-386
Flow-Mediated Dilatation Assessment in Women with Preeclampsia Compared to Women with Gestational Hypertension
Objectives. To assess flow-mediated dilatation (FMD) in women with preeclampsia (PE) versus gestational hypertension (GH) and to determine if results of this ultrasound method vary with modifications to the technique. Methods. Pregnant women with hypertension (BP ≥ 140/90 mmHg) were recruited. Women were allocated to the PE group if they had proteinuria ≥300 mg/24 h. FMDo was calculated from the percentage difference in baseline and post-occlusion (PO) diameter at 45–60 s and FMDmax from baseline and maximum diameter between 45 and 90 s. FMDmax was adjusted for hematocrit and shear rate. Results. FMDo (m ± SD) was similar (p = 0.83) in the no medication GH (5.3 ± 3.2; n = 15) and the PE (6.5 ± 4.1; n = 13) groups. FMDo was reduced (p < 0.001) in the medication GH (3.7 ± 2.8; n = 23) versus the PE (8.8 ± 4.3; n = 25) groups. For FMDmax the interaction between group and medication was not significant (both p = 0.08) in unadjusted analysis or analysis adjusted for covariates hematocrit (p = 0.023) and shear rate (p = 0.007). Means averaged over medication are presented. FMDmax was reduced (p < 0.0001) in the GH (5.7 ± 4.0; n = 38) versus the PE group (9.2 ± 4.0; n = 38). Of the PE women, 79% (30/38) reached maximum dilatation by 90 s compared with 63% (24/38) of the GH women (chi-square, p = 0.16). Conclusions. The FMDmax analysis revealed reduced FMD in GH women compared with PE women. We therefore hypothesize that PE may be a different disease to GH. Our work demonstrates differing results in FMDo and FMDmax because of modifications in the technique. Previous work on PE and FMD may not be definitive due to this evolving technique.
- 21 December 2010
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 31 (4) , 377-386
Flow-Mediated Dilatation Assessment in Women with Preeclampsia Compared to Women with Gestational Hypertension
Objectives. To assess flow-mediated dilatation (FMD) in women with preeclampsia (PE) versus gestational hypertension (GH) and to determine if results of this ultrasound method vary with modifications to the technique. Methods. Pregnant women with hypertension (BP ≥ 140/90 mmHg) were recruited. Women were allocated to the PE group if they had proteinuria ≥300 mg/24 h. FMDo was calculated from the percentage difference in baseline and post-occlusion (PO) diameter at 45–60 s and FMDmax from baseline and maximum diameter between 45 and 90 s. FMDmax was adjusted for hematocrit and shear rate. Results. FMDo (m ± SD) was similar (p = 0.83) in the no medication GH (5.3 ± 3.2; n = 15) and the PE (6.5 ± 4.1; n = 13) groups. FMDo was reduced (p < 0.001) in the medication GH (3.7 ± 2.8; n = 23) versus the PE (8.8 ± 4.3; n = 25) groups. For FMDmax the interaction between group and medication was not significant (both p = 0.08) in unadjusted analysis or analysis adjusted for covariates hematocrit (p = 0.023) and shear rate (p = 0.007). Means averaged over medication are presented. FMDmax was reduced (p < 0.0001) in the GH (5.7 ± 4.0; n = 38) versus the PE group (9.2 ± 4.0; n = 38). Of the PE women, 79% (30/38) reached maximum dilatation by 90 s compared with 63% (24/38) of the GH women (chi-square, p = 0.16). Conclusions. The FMDmax analysis revealed reduced FMD in GH women compared with PE women. We therefore hypothesize that PE may be a different disease to GH. Our work demonstrates differing results in FMDo and FMDmax because of modifications in the technique. Previous work on PE and FMD may not be definitive due to this evolving technique.
- 19 March 2008
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 115 (6) , 780-784
The relationship between cigarette smoking, endothelial function and intrauterine growth restriction in human pregnancy
This study examined the relationship of cigarette smoking and endothelial function in pregnant women by comparing smokers with nonsmokers. Endothelial function was assessed at 28–32 weeks of gestation by flow‐mediated dilatation (FMD) using ultrasound of the brachial artery. The initial FMD was significantly different between the smoking group (n = 21) at 4.0 ± 2.3, indicating endothelial dysfunction, and the nonsmoking group (n = 20) at 9.7 ± 4.0 (P < 0.001). After smoking, this difference in the groups persisted. Babies who were growth restricted (<10th percentile) had mothers with a significantly lower FMD, that is endothelial dysfunction. This work demonstrates persistent endothelial dysfunction in smoking pregnant women.
- 19 March 2008
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 115 (6) , 780-784
The relationship between cigarette smoking, endothelial function and intrauterine growth restriction in human pregnancy
This study examined the relationship of cigarette smoking and endothelial function in pregnant women by comparing smokers with nonsmokers. Endothelial function was assessed at 28–32 weeks of gestation by flow‐mediated dilatation (FMD) using ultrasound of the brachial artery. The initial FMD was significantly different between the smoking group (n = 21) at 4.0 ± 2.3, indicating endothelial dysfunction, and the nonsmoking group (n = 20) at 9.7 ± 4.0 (P < 0.001). After smoking, this difference in the groups persisted. Babies who were growth restricted (<10th percentile) had mothers with a significantly lower FMD, that is endothelial dysfunction. This work demonstrates persistent endothelial dysfunction in smoking pregnant women.
- 1 January 2007
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 26 (3) , 273-281
A Longitudinal Study Using Ultrasound to Assess Flow-Mediated Dilatation in Normal Human Pregnancy
To develop normal ranges of endothelial function in normal human pregnancy to use as a screening test for preeclampsia. In this longitudinal study, women were studied five times during pregnancy and once postpartum using flow-mediated dilatation (FMD). FMD is a noninvasive ultrasound technique used to assess endothelial function. Healthy nonpregnant women were controls. FMD increased non-significantly in pregnancy until 32 weeks, when it decreased significantly at 36+ weeks (n = 47). The fall in FMD in the third trimester has not been previously reported. This indicates the importance of gestational age when assessing FMD as a screening test for preeclampsia.
- 1 January 2007
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 26 (3) , 273-281
A Longitudinal Study Using Ultrasound to Assess Flow-Mediated Dilatation in Normal Human Pregnancy
To develop normal ranges of endothelial function in normal human pregnancy to use as a screening test for preeclampsia. In this longitudinal study, women were studied five times during pregnancy and once postpartum using flow-mediated dilatation (FMD). FMD is a noninvasive ultrasound technique used to assess endothelial function. Healthy nonpregnant women were controls. FMD increased non-significantly in pregnancy until 32 weeks, when it decreased significantly at 36+ weeks (n = 47). The fall in FMD in the third trimester has not been previously reported. This indicates the importance of gestational age when assessing FMD as a screening test for preeclampsia.